The innovative drug concept fluctuated and rebounded. Laimei Pharmaceuticals rose more than 15%, while Zhaoyan New Pharmaceutical, Medici, Chengdu Pioneer, Rongchang Biotech, and Near Shore Protein surged ahead. According to the news, BeiGene announced that revenue for 2026 is expected to be between RMB 46.3 billion and RMB 47 billion, up from the previous forecast of RMB 44.9 billion to RMB 46.2 billion. Earlier, China Biopharmaceutical announced that it signed a strategic option and licensing agreement with multinational pharmaceutical company Boehringer Ingelheim. The total transaction amount reached about 7 billion US dollars, covering 6 pre-clinical oncology assets.
Zhitongcaijing · 4d ago
Share
Listen to the news
The innovative drug concept fluctuated and rebounded. Laimei Pharmaceuticals rose more than 15%, while Zhaoyan New Pharmaceutical, Medici, Chengdu Pioneer, Rongchang Biotech, and Near Shore Protein surged ahead. According to the news, BeiGene announced that revenue for 2026 is expected to be between RMB 46.3 billion and RMB 47 billion, up from the previous forecast of RMB 44.9 billion to RMB 46.2 billion. Earlier, China Biopharmaceutical announced that it signed a strategic option and licensing agreement with multinational pharmaceutical company Boehringer Ingelheim. The total transaction amount reached about 7 billion US dollars, covering 6 pre-clinical oncology assets.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending